Cultural, geographical and ethical questions when looking to enroll pediatric patients in rare disease clinical trials

被引:6
|
作者
Anzelewicz, Stefan [1 ]
Garnier, Hanna [1 ]
Rangaswami, Arun [2 ]
Czauderna, Piotr [1 ]
机构
[1] Med Univ Gdansk, Dept Surg & Urol Children & Adolescents, Gdansk, Poland
[2] Stanford Univ, Dept Pediat, Div Hematol & Oncol, Stanford, CA 94305 USA
来源
EXPERT OPINION ON ORPHAN DRUGS | 2017年 / 5卷 / 08期
关键词
Rare diseases; pediatrics; ethics; culture; geography; patient recruitment; social support; interdisciplinary communication; registries; patient selection; internet; LABEL DRUG-USE; HEALTH RESEARCH; PRIORITY; HISTORY; TUMOR; HEPATOBLASTOMA; GLOBALIZATION; EXPERIENCE; GENETICS; CHILDREN;
D O I
10.1080/21678707.2017.1348293
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Rare diseases are becoming increasingly recognized worldwide as an important public health challenge and Orphan Drugs begin to play an important role in Research and Development. There are several major issues concerning conducting clinical trials in the field of Rare Diseases, especially in children, as 80% of those diseases are genetic in origin and involve, in most instances, children. Areas covered: This review concentrates on challenges associated with the patient recruitment process. The authors experience and opinion was complemented by a systematic search of relevant literature and includes ethical, cultural and geographical issues with rare diseases. The review presents current opinion and provides valuable support for planning and conducting clinical research in rare diseases. Expert opinion: The expert opinion section concentrates on importance of future rare disease clinical research in the context of understanding common diseases and developing new treatment options.
引用
收藏
页码:613 / 621
页数:9
相关论文
共 4 条
  • [1] Ethical and cross cultural questions concerning pediatric clinical trials
    Pilpel, D
    Leavitt, FJ
    ElizurLeiberman, E
    CONTROLLED CLINICAL TRIALS, 1996, 17 (03): : 201 - 208
  • [2] Accounting for the rarity of the disease when designing clinical trials with a focus on pediatric cancers
    Mauguen, Audrey
    CLINICAL TRIALS, 2022, 19 (03) : 292 - 296
  • [3] Widening Patient Engagement for Rare Disease Drug Trials: The Perspectives of Patients With Idiopathic Pulmonary Fibrosis on Participating in Clinical Drug Trials and Drug Trial Design
    Frost, Julia
    Mandizha, Jessica
    Jones, Steve
    van den Dungen, Chantal
    Asare, Lauren
    Pope, Catherine
    HEALTH EXPECTATIONS, 2025, 28 (02)
  • [4] Difference in Clinical Phenotype, Mutation Position, and Structural Change of RNF213 Rare Variants Between Pediatric and Adult Japanese Patients with Moyamoya Disease
    Nomura, Shunsuke
    Akagawa, Hiroyuki
    Yamaguchi, Koji
    Azuma, Kenko
    Nakamura, Akikazu
    Fukui, Atsushi
    Matsuzawa, Fumiko
    Aihara, Yasuo
    Ishikawa, Tatsuya
    Moteki, Yosuke
    Chiba, Kentaro
    Hashimoto, Kazutoshi
    Morita, Shuhei
    Ishiguro, Taichi
    Okada, Yoshikazu
    Vetiska, Sandra
    Andrade-Barazarte, Hugo
    Radovanovic, Ivan
    Kawashima, Akitsugu
    Kawamata, Takakazu
    TRANSLATIONAL STROKE RESEARCH, 2024, 15 (06) : 1142 - 1153